2. JAK/STAT Signaling Stem Cell/Wnt
  3. STAT
  4. MEAP

MEAP  (Synonyms: 2-(4-Morpholinoanilino-6-[(2-exo-norbornyl) amino)-purine)

Cat. No.: HY-183628
Handling Instructions Technical Support

MEAP (2-(4-Morpholinoanilino-6-[(2-exo-norbornyl) amino)-purine) is a NEDD9-STAT3 modulator. MEAP disrupts NEDD9-STAT3 interaction, driving STAT3 Y705 dephosphorylation. MEAP induces G2/M phase arrest. MEAP can be used for the research of anaplastic thyroid cancer.

For research use only. We do not sell to patients.

MEAP

MEAP Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

MEAP Related Antibodies

Top Publications Citing Use of Products

View All STAT Isoform Specific Products:

View All Isoforms
STAT3 STAT5 STAT6 STAT1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

MEAP (2-(4-Morpholinoanilino-6-[(2-exo-norbornyl) amino)-purine) is a NEDD9-STAT3 modulator. MEAP disrupts NEDD9-STAT3 interaction, driving STAT3 Y705 dephosphorylation. MEAP induces G2/M phase arrest. MEAP can be used for the research of anaplastic thyroid cancer[1].

IC50 & Target[1]

STAT3

 

In Vitro

MEAP potently inhibits AURKA, AURKB, AURKC, and FAK kinases in a cell-free biochemical assay[1].
MEAP potently induces centrosome-mediated microtubule nucleation in THJ-16T anaplastic thyroid cancer cells[1].
MEAP (1-5 μM) increases pericentriolar material accumulation at less active centrosomes during interphase and early mitosis in THJ-16T anaplastic thyroid cancer cells with normal centrosome numbers[1].
MEAP significantly increases pericentriolar material recruitment to supernumerary centrosomes in interphase THJ-11T and THJ-16T anaplastic thyroid cancer cells[1].
MEAP (300 nM; 48 h) preferentially induces spindle multipolarity by activating inactive supernumerary centrosomes in ALDH+ THJ-11T and THJ-16T anaplastic thyroid cancer cells, without changing centrosome amplification or fragmentation rates[1].
MEAP (300 nM; 48 h) induces selective G2/M phase arrest in ALDH+ THJ-16T anaplastic thyroid cancer cells, without selective apoptosis or senescence relative to ALDH− cells[1].
MEAP (300 nM; 96 h) reduces the ALDH+ anaplastic thyroid cancer cell population by over 80% in THJ-11T, THJ-16T, and 8505c cells via selective growth inhibition, with a dose-dependent response in THJ-16T cells[1].
MEAP (0.1-1 μM) pretreatment dose-dependently suppresses tumorsphere formation in THJ-11T, THJ-16T, and 8505c anaplastic thyroid cancer cells, attenuating stemness[1].
MEAP (100 nM; 5-60 min) selectively induces rapid dephosphorylation of STAT3Y705 in ALDH+ THJ-16T anaplastic thyroid cancer cells, while nonselectively reducing phosphorylated Aurora-A levels[1].
MEAP (100 nM; 10 min) disrupts the NEDD9-STAT3 protein interaction in ALDH+ THJ-16T anaplastic thyroid cancer cells within 10 minutes[1].
MEAP (100 nM; 15 min) reduces colocalization of NEDD9 and phosphorylated STAT3Y705 in ALDH+ THJ-16T anaplastic thyroid cancer cells, altering their intracellular localization[1].
MEAP (100 nM; 24 h) induces centrosome microtubule nucleation and γ-tubulin accumulation in ALDH+ THJ-16T anaplastic thyroid cancer cells in a NEDD9-STAT3-dependent manner[1].
MEAP reduces chromosome missegregation in ALDH+ THJ-16T anaplastic thyroid cancer cells in a NEDD9-STAT3-dependent manner[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MEAP Related Antibodies

Immunofluorescence[1]

Cell Line: Sorted ALDH+ and ALDH- THJ-11T and THJ-16T anaplastic thyroid cancer cells
Concentration: 300 nM
Incubation Time: 48 h
Result: Reduced the percentage of inactive mitotic centrosomes in ALDH+ THJ-11T and THJ-16T cells.
Increased spindle multipolarity (32% in ALDH+ cells vs. 8% in ALDH- cells) and decreased pseudobipolar spindles in ALDH+ cells.
Did not alter the frequency of centrosome amplification or centrosome fragmentation.

Cell Cycle Analysis[1]

Cell Line: Sorted ALDH+ and ALDH- THJ-16T anaplastic thyroid cancer cells
Concentration: 300 nM
Incubation Time: 1 h; 24 h; 48 h
Result: Induced G2/M phase accumulation in ALDH+ cells (reaching 15% of cells in G2/M by 48 hours) but not in ALDH- cells.
Did not cause selective apoptosis or senescence in ALDH+ cells relative to ALDH- cells.

Western Blot Analysis[1]

Cell Line: Sorted ALDH+ and ALDH- THJ-16T anaplastic thyroid cancer cells
Concentration: 100 nM
Incubation Time: 5 min; 15 min; 30 min; 45 min; 60 min
Result: Rapidly depleted pSTAT3-Y705 levels in ALDH+ cells within 5 minutes, with no change in ALDH- cells.
Reduced phosphorylated Aurora-A levels nonselectively in both ALDH+ and ALDH- cells.
Did not alter total STAT3, total Aurora-A, or NEDD9 protein levels.

Immunofluorescence[1]

Cell Line: ALDH+ THJ-16T anaplastic thyroid cancer cells
Concentration: 100 nM
Incubation Time: 15 min
Result: Reduced colocalization of NEDD9 and pSTAT3-Y705, with Pearson's R value decreasing from 0.83 (DMSO) to 0.33.
Decreased cytoplasmic pSTAT3-Y705 staining and redistributed NEDD9 from the perinuclear region.
In Vivo

MEAP (30 mg/kg; i.p.; 3 total doses on days 15, 17, and 20) selectively eliminates ALDH+ ATC cell clusters, increases centrosome symmetry, induces spindle multipolarity, and reduces chromosomal instability in an orthotopic mouse model[1].
MEAP (30 mg/kg; i.p.; triweekly; 4 weeks) drives a robust antitumor response with ~4-fold tumor volume reduction relative to controls and no apparent host toxicity in a subcutaneous ATC mouse model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NOD-SCID (female, 6- to 8-week-old, orthotopic model with 5 × 105 8505c ATC cells injected into right thyroid gland)[1]
Dosage: 30 mg/kg
Administration: i.p.; 3 total doses on day 15, 17, and 20
Result: Eliminated detectable ALDH1-positive cell clusters in tumors.
Increased the γ-tubulin weak/strong centrosome symmetry ratio from 0.29 to 0.74.
Increased the percentage of mitotic cells with multipolar spindles to ~15%.
Reduced the percentage of mitotic cells with missegregated chromosomes to ~40%.
Animal Model: NOD-SCID (female, 6- to 8-week-old, subcutaneous model with 8505c ATC cells implanted subcutaneously, treatment initiated when tumors reached 40-80 mm3)[1]
Dosage: 30 mg/kg
Administration: i.p.; triweekly for 4 weeks
Result: Resulted in a ~4-fold reduction in tumor volume compared with vehicle controls.
Outperformed Taxol in suppressing ATC tumor growth.
Caused no detectable toxicity or body weight loss.
Molecular Weight

447.58

Formula

C25H33N7O
SMILES

C[C@@H]1[C@H](C[C@H]2C[C@@H]1C2(C)C)NC3=C4N=CNC4=NC(NC5=CC=C(C=C5)N6CCOCC6)=N3
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

MEAP Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MEAP2-(4-Morpholinoanilino-6-[(2-exo-norbornyl) amino)-purineSTATanaplastic thyroid cancerNEDD9-STAT3 interactionpericentriolar accumulationSTAT3 Y705spindle multipolarityG2/M phase arrestcentrosome microtubule nucleationNEDD9-STAT3 signaling axissupernumerary centrosomesTHJ-16TInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
MEAP
Cat. No.:
HY-183628
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.